Sinovac COVID-19 vaccine
北京科兴中维新冠疫苗
Four vaccines are currently approved for use in the EU: Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson. Another four are under "rolling review" for possible approval: Russia's Sputnik, China's Sinovac, Germany's CureVac and Novavax of the United States. (straitstimes.com/July 01, 2021)

Sinopharm COVID-19 vaccine (Beijing)
国药北京所新冠疫苗
Another vaccine developed by a Beijing-based institute linked to Sinopharm, which this month obtained emergency use approval by the World Health Organization (WHO), showed a 78.1% efficacy, the paper said. The readings were based on calculations over 142 symptomatic cases in a trial involving more than 40,000 participants, with 26 injected with the Wuhan unit's vaccine and 21 with the Beijing unit's shot, it said. (BBC/May 27, 2021)

Sinopharm COVID-19 vaccine (Wuhan)
国药中生武汉公司新型冠状疫苗
A vaccine developed by a Wuhan-based subsidiary of Sinopharm was 72.8% effective against symptomatic COVID-19 at least two weeks after second injection, based on interim results, the peer-reviewed study published in the Journal of the American Medical Association showed on Wednesday. (reuters.com/May 27, 2021)
CanSinoBIO COVID-19 vaccine
康希诺生物新冠疫苗
CanSino Biologics, often abbreviated as CanSinoBIO, is a Chinese vaccine company. This Chinese company has developed a COVID vaccine based on an adenovirus in partnership with the Chinese Academy of Military Medical Sciences. The adenovirus is unable to cause disease itself, but is used to deliver a coronavirus protein. (theconversation.com/)

Zifivax COVID-19 vaccine
安徽智飞新冠疫苗
Chinese-based company, Anhui Zhifei Longcom, has developed a protein subunit COVID-19 vaccine known as Zifivax COVID-19 vaccine. Subunit vaccines use a purified piece of the virus, a protein, to trigger an immune response. It has recently started phase 3 clinical trials. There hasn’t yet been any announcement or published report of the results of phase 1 and 2 trials. (theconversation.com/)

Indonesia has approved a COVID-19 vaccine produced by Chinese company Anhui Zhifei Longcom Biopharmaceutical for emergency use, the country's food and drug agency BPOM said on Thursday.
"Today, BPOM again announces that we have approved a COVID-19 vaccine product under the trade name Zifivax, which was developed with a recombinant protein sub-unit platform," BPOM's head Penny Lukito told a virtual press conference. (news.cgtn.com)
TB北京中文旅游服务
北京外宾旅游
北京外宾特色旅游
北京外宾旅行指南
北京包车旅游
北京参团旅游
北京长城徒步游
北京租车服务
北京定制旅游
TB北京英文旅游服务
Beijing Tour
Great Wall Tour
Beijing Tour Packages
Beijing Day Tour
Beijing Group Tour
Beijing Winter Tour
Car Rental in Beijing
Create My Beijing Trip
TB 英语
环球旅游英语
健康生活英语
新闻英语词汇
生活英语词汇
英语文学词汇
英语咬文嚼字
英汉智慧语录






版权声明:本文为原创文章,版权归 admin 所有,欢迎分享本文,转载请保留出处!